A report from the IQVIA Institute for Human Data Science identified areas to watch through 2023.
Ding is a nine-year veteran of Astellas.
Wolfe Research analysts say the market is underestimating the vaccine’s potential by more than $2 billion.
Xeomin, made by Merz, is hoping to differentiate itself in a market dominated by Allergan’s Botox.
National ad spend grew 7% year-over-year across all categories and platforms including pharma in October.
Robert Zirkelbach, public affairs EVP at PhRMA, discussed the group’s legislative priorities at the Coalition for Healthcare Communication’s post-election conference on Tuesday.
The drugmaker will raise prices on 10% of its drug portfolio.
The Trump administration has proposed basing Medicare Part B drug prices on what other countries pay.
The drugmaker has refocused on ethics to move past the Michael Cohen scandal.
Teva’s Ajovy becomes the second approved CGRP migraine therapy, following Amgen’s Aimovig.
MM+M is proud to announce the fourth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators.
Get the most out of
Register for free and enjoy unlimited access to: